Do we need Phase 3 trials in oncology?

Do we need Phase 3 trials in oncology? #Oncology #ClinicalTrials #Phase3Trials #CancerResearch #RWE #EvidenceBasedMedicine #DrugDevelopment #MedicalResearch #HealthcarePolicy #Pharmaceuticals #PrecisionMedicine #ClinicalInnovation #CancerCare #Biostatistics #ConsiliumScientific Are Phase 3 trials still essential in cancer research, or are they becoming inefficient and outdated? As oncology evolves, researchers are questioning whether traditional trial models truly deliver meaningful patient benefit. About This Video In this expert-led discussion, leading voices in oncology, policy, and research examine the role of Phase 3 trials in modern cancer drug development. While Oncology has made major advances, concerns remain about inefficiencies, rising costs, and limited patient benefit from many newly approved therapies. Some argue that large Phase 3 trials are critical for validating safety and effectiveness, while others question whether they contribute to research waste. The panel explores whether alternative approaches like Real-world evidence, adaptive trials, and synthetic control arms could complement or even replace traditional randomized controlled trials in certain settings. What You Will Learn ✅ The role of Phase 3 trials in cancer drug approval ✅ Why some researchers argue there is waste in oncology research ✅ How real-world evidence compares to randomized trials ✅ The risks of relying on surrogate endpoints ✅ Whether new trial designs can improve efficiency and outcomes Main Topic of This Video This seminar explores whether Phase 3 trials remain the gold standard in oncology or if new evidence models and trial designs can better serve patients, researchers, and healthcare systems. Key Topics Covered in This Video The purpose and limitations of Phase 3 trials Research waste in oncology Use of surrogate endpoints vs survival outcomes Real-world evidence and its limitations Synthetic comparators in clinical trials Incentives in pharmaceutical development Challenges with single-arm studies Balancing speed, safety, and clinical value Why This Video Is Important Cancer research continues to attract major investment, yet questions remain about how much real clinical value is delivered to patients. Some therapies receive approval based on limited or indirect evidence, creating uncertainty about their true impact on survival and quality of life. At the same time, Phase 3 trials are expensive, time-consuming, and not always feasible in rapidly evolving treatment landscapes. This discussion highlights the need to balance innovation with rigorous evidence, ensuring that new cancer treatments provide meaningful benefit while reducing unnecessary research waste. Speakers Chair: Leeza Osipenko Marty Tanenbaum Julian Adams Ian Tannock Jonathan Kimmelman Timestamps 00:00 Introductions and panel overview 07:45 The purpose of Phase 3 trials 18:20 Research waste in oncology 27:10 Surrogate endpoints vs real outcomes 36:40 Role of real-world evidence 45:15 Synthetic comparators and trial design 54:30 Incentives and market challenges 01:03:10 Final discussion and conclusions Phase 3 trials oncology, cancer clinical trials debate, real-world evidence oncology, surrogate endpoints cancer research, randomized controlled trials vs RWE, oncology drug development challenges, clinical trial design innovation, cancer research policy, pharmaceutical incentives oncology, evidence-based cancer treatment, oncology research waste, synthetic control arms trials 📲 STAY CONNECTED with Consilium Scientific X: @consiliumsci LinkedIn:   / consilium-scientific   Instagram: @consilium.scientific Substack: https://healthontrial.substack.com/ If you found this discussion valuable, LIKE, SUBSCRIBE, and SHARE to support evidence-based healthcare conversations. Comment below: Do you think Phase 3 trials are still necessary, or should oncology move toward new evidence models? ⚠️ IMPORTANT DISCLAIMER The information shared on this channel is intended for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Viewers should consult qualified healthcare professionals for medical concerns or decisions. Consilium Scientific aims to promote research transparency and evidence-based discussion. Opinions expressed by speakers or guests are their own and do not necessarily reflect the official views of Consilium Scientific. While we strive for accuracy and scientific integrity, we do not guarantee completeness or that all information is free from error. This content should not be used as a substitute for professional medical consultation or regulatory guidance.